{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T15:27:53Z","timestamp":1696174073491},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Virol J"],"published-print":{"date-parts":[[2014,12]]},"DOI":"10.1186\/1743-422x-11-93","type":"journal-article","created":{"date-parts":[[2014,5,16]],"date-time":"2014-05-16T17:02:32Z","timestamp":1400259752000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Virologic characterization of genotype 4 hepatitis C virus variants in patients treated with telaprevir"],"prefix":"10.1186","volume":"11","author":[{"given":"Sandra","family":"De Meyer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne","family":"Ghys","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Inge","family":"Dierynck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maria","family":"Beumont","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donghan","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gaston","family":"Picchio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,5,16]]},"reference":[{"key":"2414_CR1","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1046\/j.1365-2893.1999.6120139.x","volume":"6","author":"WHO","year":"1999","unstructured":"WHO: Global surveillance and control of hepatitis c. report of a who consultation organized in collaboration with the viral hepatitis prevention board, Antwerp, Belgium. J Viral Hepat 1999, 6: 35-47.","journal-title":"J Viral Hepat"},{"key":"2414_CR2","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1002\/hep.20819","volume":"42","author":"P Simmonds","year":"2005","unstructured":"Simmonds P, Bukh J, Combet C, Del\u00e9age G, Enomoto N, Feinstone S, Halfon P, Inchausp\u00e9 G, Kuiken C, Maertens G, Mizokami M, Murphy DG, Okamoto H, Pawlotsky JM, Penin F, Sablon E, Shin-I T, Stuyver LJ, Thiel HJ, Viazov S, Weiner AJ, Widell A: Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes. Hepatology 2005, 42: 962-973. 10.1002\/hep.20819","journal-title":"Hepatology"},{"key":"2414_CR3","doi-asserted-by":"publisher","first-page":"41","DOI":"10.7150\/ijms.3.41","volume":"3","author":"T Sy","year":"2006","unstructured":"Sy T, Jamal MM: Epidemiology of hepatitis C virus (HCV) infection. Int J Med Sci 2006, 3: 41-46.","journal-title":"Int J Med Sci"},{"key":"2414_CR4","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1002\/hep.22127","volume":"47","author":"SM Kamal","year":"2008","unstructured":"Kamal SM, Nasser IA: Hepatitis C genotype 4: what we know and what we don\u2019t yet know. Hepatology 2008, 47: 1371-1383. 10.1002\/hep.22127","journal-title":"Hepatology"},{"key":"2414_CR5","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1186\/1471-2334-11-208","volume":"11","author":"PT Dias","year":"2011","unstructured":"Dias PT, Hahn JA, Delwart E, Edlin B, Martin J, Lum P, Evans J, Kral A, Deeks S, Busch MP, Page K: Temporal changes in HCV genotype distribution in three different high risk populations in San Francisco California. BMC Infect Dis 2011, 11: 208. 10.1186\/1471-2334-11-208","journal-title":"BMC Infect Dis"},{"key":"2414_CR6","doi-asserted-by":"publisher","first-page":"3040","DOI":"10.1128\/JCM.00457-11","volume":"49","author":"JJ Germer","year":"2011","unstructured":"Germer JJ, Mandrekar JN, Bendel JL, Mitchell PS, Yao JD: Hepatitis C virus genotypes in clinical specimens tested at a national reference testing laboratory in the United States. J Clin Microbiol 2011, 49: 3040-3043. 10.1128\/JCM.00457-11","journal-title":"J Clin Microbiol"},{"key":"2414_CR7","unstructured":"INCIVEK\u00ae (telaprevir) US FDA Prescribing InformationAvailable from: . Accessed May 7 2014 \n                    http:\/\/pi.vrtx.com\/files\/uspi_telaprevir.pdf\n                    \n                   Available from: . Accessed May 7 2014"},{"key":"2414_CR8","unstructured":"INCIVO\u00ae (telaprevir) EU Summary of Product CharacteristicsAvailable from: . Accessed May 7 2014 \n                    http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002313\/WC500115529.pdf\n                    \n                   Available from: . Accessed May 7 2014"},{"key":"2414_CR9","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1056\/NEJMoa1013086","volume":"364","author":"S Zeuzem","year":"2011","unstructured":"Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S, Focaccia R, Younossi Z, Foster GR, Horban A, Ferenci P, Nevens F, M\u00fcllhaupt B, Pockros P, Terg R, Shouval D, van Hoek B, Weiland O, Van Heeswijk R, De Meyer S, Luo D, Boogaerts G, Polo R, Picchio G, Beumont M: REALIZE study team: telaprevir for retreatment of HCV infection. N Engl J Med 2011, 364: 2417-2428. 10.1056\/NEJMoa1013086","journal-title":"N Engl J Med"},{"key":"2414_CR10","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1053\/j.gastro.2009.11.055","volume":"138","author":"C Sarrazin","year":"2010","unstructured":"Sarrazin C, Zeuzem S: Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology 2010, 138: 447-462. 10.1053\/j.gastro.2009.11.055","journal-title":"Gastroenterology"},{"key":"2414_CR11","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1053\/j.gastro.2007.02.037","volume":"132","author":"C Sarrazin","year":"2007","unstructured":"Sarrazin C, Kieffer TL, Bartels D, Hanzelka B, M\u00fch U, Welker M, Wincheringer D, Zhou Y, Chu HM, Lin C, Weegink C, Reesink H, Zeuzem S, Kwong AD: Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 2007, 132: 1767-1777. 10.1053\/j.gastro.2007.02.037","journal-title":"Gastroenterology"},{"key":"2414_CR12","doi-asserted-by":"publisher","first-page":"e34372","DOI":"10.1371\/journal.pone.0034372","volume":"7","author":"TL Kieffer","year":"2012","unstructured":"Kieffer TL, De Meyer S, Bartels DJ, Sullivan JC, Zhang EZ, Tigges A, Dierynck I, Spanks J, Dorrian J, Jiang M, Adiwijaya B, Ghys A, Beumont M, Kauffman RS, Adda N, Jacobson IM, Sherman KE, Zeuzem S, Kwong AD, Picchio G: Hepatitis C viral evolution in genotype 1 treatment-na\u00efve and treatment-experienced patients receiving telaprevir-based therapy in clinical trials. PLoS One 2012, 7: e34372. 10.1371\/journal.pone.0034372","journal-title":"PLoS One"},{"issue":"Suppl S1","key":"2414_CR13","doi-asserted-by":"publisher","first-page":"S8","DOI":"10.1016\/S0168-8278(07)61610-9","volume":"46","author":"C Lin","year":"2007","unstructured":"Lin C, Hanzelka B, Muh U, Kovari L, Bartels DJ, Tigges AM, Miller J, Rao BG, Kwong AD: Telaprevir (VX-950) is a potent inhibitor of HCV NS3-4A proteases derived from genotype non-1 HCV infected patients. J Hepatol 2007,46(Suppl S1):S8.","journal-title":"J Hepatol"},{"key":"2414_CR14","doi-asserted-by":"publisher","first-page":"1433","DOI":"10.1002\/hep.24641","volume":"54","author":"MG Ghany","year":"2011","unstructured":"Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB: An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the study of liver diseases. Hepatology 2011, 54: 1433-1444. 10.1002\/hep.24641","journal-title":"Hepatology"},{"key":"2414_CR15","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1111\/j.1365-2893.2006.00823.x","volume":"14","author":"D Roulot","year":"2007","unstructured":"Roulot D, Bourcier V, Grando V, Deny P, Baazia Y, Fontaine H, Bailly F, Castera L, De Ledinghen V, Marcellin P, Poupon R, Bourli\u00e8re M, Zarski JP, Roudot-Thoraval F: Observational VHC4 Study Group: epidemiological characteristics and response to peginterferon plus ribavirin treatment of hepatitis C virus genotype 4 infection. J Viral Hepat 2007, 14: 460-467. 10.1111\/j.1365-2893.2006.00823.x","journal-title":"J Viral Hepat"},{"key":"2414_CR16","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1093\/infdis\/jit274","volume":"208","author":"Y Benhamou","year":"2013","unstructured":"Benhamou Y, Moussalli J, Ratziu V, Lebray P, De Backer K, De Meyer S, Ghys A, Luo D, Picchio GR, Beumont M: Telaprevir activity in treatment-naive patients infected hepatitis C virus genotype 4: a randomized trial. J Infect Dis 2013, 208: 1000-1007. 10.1093\/infdis\/jit274","journal-title":"J Infect Dis"},{"key":"2414_CR17","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1002\/hep.21774","volume":"46","author":"N Forestier","year":"2007","unstructured":"Forestier N, Reesink HW, Weegink CJ, McNair L, Kieffer TL, Chu HM, Purdy S, Jansen PL, Zeuzem S: Antiviral activity of telaprevir (VX-950) and peginterferon alfa-2a in patients with hepatitis C. Hepatology 2007, 46: 640-648. 10.1002\/hep.21774","journal-title":"Hepatology"},{"key":"2414_CR18","unstructured":"Kieffer T, Bartels D, Sullivan J, Adiwijaya BS, Zhang EZ, Tigges A, Dorrian J, Spanks J, De Meyer W, Picchio G, Adda N, Kwong AD 61st Annual Meeting of the American Association for the Study of Liver Diseases, Boston, MA, October 29\u2013November 2, 2010. Abstract LB-11. Clinical virology results from telaprevir Phase 3 study ADVANCE"},{"key":"2414_CR19","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1111\/jvh.12046","volume":"20","author":"S De Meyer","year":"2013","unstructured":"De Meyer S, Ghys A, Foster GR, Beumont M, Van Baelen B, Lin TI, Dierynck I, Ceulemans H, Picchio G: Analysis of genotype 2 and 3 HCV variants in patients treated with telaprevir demonstrates a consistent resistance profile across genotypes. J Viral Hepat 2013, 20: 395-403. 10.1111\/jvh.12046","journal-title":"J Viral Hepat"},{"issue":"Suppl","key":"2414_CR20","first-page":"436A","volume":"52","author":"S Zeuzem","year":"2010","unstructured":"Zeuzem S, Sulkowski M, Zoulim F, Sherman KE, Alberti A, Wei LJ, van Baelen B, Sullivan J, Kieffer TL, De Meyer S, Picchio G, Tomaka F, Graham CS8, McHutchison JG: Long-term follow-up of patients with chronic hepatitis C treated with telaprevir in combination with peginterferon alfa-2a and ribavirin: interim analysis of the EXTEND study. Hepatology 2010,52(Suppl):436A.","journal-title":"Hepatology"},{"key":"2414_CR21","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.antiviral.2005.12.003","volume":"70","author":"X Tong","year":"2006","unstructured":"Tong X, Chase R, Skelton A, Chen T, Wright-Minogue J, Malcolm BA: Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034. Antiviral Res 2006, 70: 28-38. 10.1016\/j.antiviral.2005.12.003","journal-title":"Antiviral Res"},{"key":"2414_CR22","doi-asserted-by":"publisher","first-page":"4784","DOI":"10.1128\/AAC.48.12.4784-4792.2004","volume":"48","author":"K Lin","year":"2004","unstructured":"Lin K, Kwong AD, Lin C: Combination of a hepatitis C virus NS3-NS4A protease inhibitor and alpha interferon synergistically inhibits viral RNA replication and facilitates viral RNA clearance in replicon cells. Antimicrob Agents Chemother 2004, 48: 4784-4792. 10.1128\/AAC.48.12.4784-4792.2004","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Virology Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1743-422X-11-93.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,22]],"date-time":"2019-01-22T03:00:49Z","timestamp":1548126049000},"score":1,"resource":{"primary":{"URL":"https:\/\/virologyj.biomedcentral.com\/articles\/10.1186\/1743-422X-11-93"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5,16]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["2414"],"URL":"https:\/\/doi.org\/10.1186\/1743-422x-11-93","relation":{},"ISSN":["1743-422X"],"issn-type":[{"value":"1743-422X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,5,16]]},"assertion":[{"value":"17 December 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2014","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2014","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"93"}}